Incidence of Acute Prostatitis Caused by Extended-spectrum β-Lactamase-producing Escherichia coli After Transrectal Prostate Biopsy


      To study the clinical and bacteriologic picture of acute prostatitis caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli after transrectal ultrasound-guided prostate biopsy.


      The retrospective data from 1339 patients who had undergone transrectal ultrasound-guided biopsy from November 2003 to June 2008 were reviewed. An automatic biopsy gun with an 18-gauge needle was used to obtain 10-core biopsies for first biopsies and ≥12-core for repeat biopsies. These patients had received 500 mg ciprofloxacin orally twice daily for 5 days, beginning 24 hours before biopsy. All biopsies were performed as outpatient procedures.


      Of the 1339 patients, 28 (2.1%) had acute bacterial prostatitis detected after transrectal ultrasound-guided prostate biopsy. Acute prostatitis occurred after the first biopsy in 15 patients (1.3%) and after repeat biopsy in 13 (6.8%). The patients had developed infective symptoms a mean of 3 days after transrectal ultrasound-guided prostate biopsy. Of the 28 patients, 17 (61%) had positive urine and/or blood cultures, including E. coli in 14. Of the 14 patients, 6 had acute prostatitis caused by ESBL-producing E. coli. Bacteria isolated from urine were tested for drug susceptibility to a wide range of antibiotics. All patients with ESBL-producing E. coli were treated with imipenem. The bacteria detected in these urine cultures were resistant to ciprofloxacin, ceftriaxone, sulbactam/ampicillin, and cefazolin. Imipenem and piperacillin-tazobactam were the most active agents against ESBL-producing E. coli. ESBL-producing isolates had a significant reduction in activity for most antimicrobial agents, including fluoroquinolones and amikacin.


      The prompt initiation of effective antimicrobial treatment is essential in patients with ESBL-producing E. coli, and empirical decisions must be determined by knowledge of the local distribution of pathogens and their susceptibility.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Crawford E.D.
        • Haynes Jr, A.L.
        • Story M.W.
        • et al.
        Prevention of urinary tract infection and sepsis following transrectal prostatic biopsy.
        J Urol. 1982; 127: 449-451
        • Lindert K.A.
        • Kabalin J.N.
        • Terris M.K.
        Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy.
        J Urol. 2000; 164: 76-80
        • Aron M.
        • Rajeev T.P.
        • Gupta N.P.
        Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study.
        BJU Int. 2000; 85: 682-685
        • Sieber P.R.
        • Rommel F.M.
        • Agusta V.E.
        • et al.
        Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy.
        J Urol. 1997; 157: 2199-2200
        • Kapoor D.A.
        • Klimberg I.W.
        • Malek G.H.
        • et al.
        Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.
        Urology. 1998; 52: 552-558
        • Shigehara K.
        • Miyagi T.
        • Nakashima T.
        • et al.
        Acute bacterial prostatitis after transrectal prostate needle biopsy: clinical analysis.
        J Infect Chemother. 2008; 14: 40-43
        • Feliciano J.
        • Teper E.
        • Ferrandino M.
        • et al.
        The incidence of fluoroquinolone resistant infections after prostate biopsy: are fluoroquinolones still effective prophylaxis?.
        J Urol. 2008; 179: 952-955
        • Ena J.
        • Arjona F.
        • Martinez-Peinado C.
        • et al.
        Epidemiology of urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli.
        Urology. 2006; 68: 1169-1174
        • Cannon Jr, G.M.
        • Smaldone M.C.
        • Paterson D.L.
        Extended spectrum beta-lactamase gram-negative sepsis following prostate biopsy: implications for use of fluoroquinolone prophylaxis.
        Can J Urol. 2007; 14: 3653-3655
        • Sabbagh R.
        • McCormack M.
        • Peloquin F.
        • et al.
        A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy.
        Can J Urol. 2004; 11: 2216-2219
      1. Grabe M, Bishop M, Bjerklund-Johansen T, et al. EAU guidelines on the management of urinary and male genital tract infections; Available at: Accessed December 14, 2008.

        • Wolf J.J.
        • Bennett C.
        • Dmochowski R.
        • et al.
        Best practice policy statement on urologic surgery antimicrobial prophylaxis.
        J Urol. 2008; 179: 1379-1390
        • Carey J.M.
        • Korman H.J.
        Transrectal ultrasound guided biopsy of the prostate: do enemas decrease clinically significant complications?.
        J Urol. 2001; 166: 82-85
        • Vallancien G.
        • Veillon B.
        Systemic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination.
        J Urol. 1991; 146: 1308
        • Tal R.
        • Livne P.M.
        • Lask D.M.
        • et al.
        Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy.
        J Urol. 2003; 169: 1762-1765
        • Otrock Z.K.
        • Oghlakian G.O.
        • Salamoun M.M.
        • et al.
        Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon.
        Infect Control Hosp Epidemiol. 2004; 25: 873-877
        • Colodner R.K.
        • Chazan B.
        • Raz R.
        Antimicrobial susceptibility of community-acquired uropathogenes in northern Israel.
        Int J Antimicrob Agents. 2001; 18: 189-192
        • Kahlmeter G.
        An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: The ECO.
        J Antimicrob Chemother. 2003; 51: 69-76
        • Aparicio J.
        • Such J.
        • Pascual S.
        • et al.
        Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences.
        J Hepatol. 1999; 31: 277-283
        • Kanafani Z.
        • Mehio-Sibai A.
        • Araj G.
        • et al.
        Epidemiology and risk factors for extended spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon.
        Am J Infect Control. 2005; 33: 326-332
        • Lautenbach E.
        • Patel J.
        • Bilker W.
        • et al.
        Extended spectrum-lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
        Clin Infect Dis. 2001; 32: 1162-1171
        • Hyle E.P.
        • Lipworth A.D.
        • Zaoutis T.E.
        • et al.
        Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended spectrum-lactamase-producing Enterobacteriaceae.
        Arch Intern Med. 2005; 165: 1375-1380
        • Melzer M.
        • Petersen I.
        Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli.
        J Infect. 2007; 55: 254-259
        • Skippen I.
        • Turton J.
        • Kaufmann M.E.
        • et al.
        Epidemiology of infections caused by extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London.
        J Hosp Infect. 2006; : 115-123

      Linked Article

      • Editorial Comment
        UrologyVol. 74Issue 1
        • Preview
          This is an excellent clinical review of a large number of patients who underwent transrectal ultrasound-guided prostate biopsy (TRUS-BP) during an almost 5-year period. All patients received ciprofloxacin, 500 mg twice daily for 5 days, starting 24 hours before the procedure. All patients underwent a minimum of a 12-core biopsy. The authors reviewed the infectious complications and noted that these occurred in 28 of 1339 patients (2.1%). A slightly greater (and statistically significant) incidence was found in patients undergoing repeat biopsy (6.8%) vs an initial biopsy (1.3%).
        • Full-Text
        • PDF